Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: A time and motion study in the United Kingdom

Journal of Medical Economics

Volumn 17, Issue 7, 2014, Pages 459-468

  Rule, Simon ^a   Collins, Graham P ^b   Samanta, Kunal ^c  

^a PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

Cost; Intravenous infusion; Rituximab; Subcutaneous; Time and motion

Indexed keywords

RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ARTICLE; CANCER PATIENT; COST CONTROL; DRUG MONITORING; HEALTH CARE COST; HEALTH CARE PERSONNEL; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; OBSERVATIONAL STUDY; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; UNITED KINGDOM; COMPARATIVE STUDY; COST; ECONOMICS; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOMA, NON-HODGKIN; NATIONAL HEALTH SERVICE; OUTPATIENT DEPARTMENT; PHASE 3 CLINICAL TRIAL (TOPIC); SUBCUTANEOUS DRUG ADMINISTRATION; TASK PERFORMANCE;

ADMINISTRATION, INTRAVENOUS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; COSTS AND COST ANALYSIS; GREAT BRITAIN; HEALTH PERSONNEL; HUMANS; INJECTIONS, SUBCUTANEOUS; LYMPHOMA, NON-HODGKIN; OUTPATIENT CLINICS, HOSPITAL; PROSPECTIVE STUDIES; STATE MEDICINE; TIME AND MOTION STUDIES;

EID: 84903162710     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2014.914033     Document Type: Article

References (15)

1. International Agency for Research on Cancer. GLOBOCAN. http://globocan. iarc.fr. Accessed January 15, 2014
2. Roche. MabThera Summary of Product Characteristics. http://www.ema. europa. eu/docs/en-GB/document-library/EPAR-Product-Information/human/000165/ WC500025821.pdf. Accessed January 15, 2014
3. Roche. MabThera- receives marketing authorization in the European Union. http://www.roche.com/static/app/news/media-news-1998-06-03-e.pdf. Accessed January 15, 2014
4. Roche. MabThera approved in Europe for first line maintenance treatment of follicular lymphoma, a common type of blood cancer. http://www.roche.com/ media/media-releases/med-cor-2010-10-29.htm. Accessed January 15, 2014
5. Tilly H, Vitolo U, Walewski J, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23:vii78-vii82
6. Dreyling M, Ghielmini M, Marcus R, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22:vi59-vi63
7. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725-32 (Pubitemid 41742196)
8. Frost GI. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv 2007;4:427-40 (Pubitemid 47249140)
9. Davies A, Merli F, Mihaljevik B, et al. Pharmacokinetics (PK), safety and overall response rate (ORR) achieved with subcutaneous (SC) administration of rituximab in combination with chemotherapy were comparable to those achieved with intravenous (IV) administration in patients ( pts) with follicular lymphoma (FL) in the first-line setting: stage 1 results of the phase III SABRINA study (BO22334). ASH Annual Meeting Abstracts 2012;120:1629
10. Salar A, Bouabdallah R, McIntyre C, et al. A two-stage phase Ib study to investigate the pharmacokinetics, safety and tolerability of subcutaneous rituximab in patients with follicular lymphoma as part of maintenance treatment. ASH Annual Meeting Abstracts 2010;116:2858
11. Barnes RM. Motion and time study: design and measurement of work. 7th edn. New York: John Wiley & Sons, 1980
12. Curtis L. Unit costs of health and social care 2012. http://www.pssru.ac. uk. Accessed January 15, 2014
13. NHS Agenda for Change-pay rates. http://www.nhscareers.nhs.uk/workingin- the-nhs/pay-and-benefits/agenda-for-change-pay-rates. Accessed January 15, 2014
14. Burcombe R, Chan S, Simcock R, et al. Subcutaneous trastuzumab (Herceptin-): a UK time and motion study in comparison with intravenous formulation for the treatment of patients with HER2-positive early breast cancer. Adv Breast Cancer Res 2013;2:133-40
15. Roche. Data on file; RXUKDATA00137. 2013